QUINTILES IMS HOLDINGS, INC. (NYSE:Q) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July25, 2017, the Board of Directors (the “Board”) of Quintiles IMS Holdings, Inc. (the “Company”) appointed Colleen A. Goggins to the Board, effective immediately. Ms. Goggins will serve as a Class II director. The Board determined that Ms.Goggins satisfies the NYSE definition of “independent director.”
In connection with her election to the Board, Ms.Goggins entered into the Company’s standard indemnification agreement with non-management directors, a copy of which is filed as Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on October3, 2016 and is incorporated herein by reference. Ms.Goggins will participate in the non-employee director compensation arrangements established by the Company for non-employee directors, as described under “Director Compensation” in the Company’s proxy statement dated February22, 2017 for its 2017 annual meeting of stockholders.
Item 5.02 Regulation FD Disclosure.
The Company issued a press release announcing the appointment of Ms.Goggins, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 5.02 Financial Statements and Exhibits.
(d) Exhibits
|
ExhibitNo. |
Description |
| 99.1 | Press Release regarding appointment of a new director dated July 25, 2017. |
Quintiles IMS Holdings, Inc. ExhibitEX-99.1 2 d432201dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 QuintilesIMS Contacts: Tor Constantino,…To view the full exhibit click here
About QUINTILES IMS HOLDINGS, INC. (NYSE:Q)
Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a provider of biopharmaceutical development services and commercial outsourcing services. It is engaged in the development and commercialization of pharmaceutical therapies. Its segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.